ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
化工社オープンプロジェクト:[email protected]AIアクセス:llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.7.8
  1. ホーム
  2. /化合物

ベンドロフルメチアジド

Bendroflumethiazide

HCID 2315
ノート反応
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
73-48-3
標準SMILES
NS(=O)(=O)c1cc2c(cc1C(F)(F)F)NC(Cc1ccccc1)NS2(=O)=O
InChIKey
HDWIHXWEUNVBIY-UHFFFAOYSA-N
分子式
C15H14F3N3O4S2
平均分子量
421.4 g/mol
単同位体質量
421.03778277

概要

Bendroflumethiazide is a sulfonamide consisting of 7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by a trifluoromethyl group and that at position 3 is substituted by a benzyl group. It has a role as a diuretic and an antihypertensive agent. It is a sulfonamide and a benzothiadiazine.

名称と識別子

優先名称
Bendroflumethiazide
IUPAC
3-benzyl-1,1-dioxo-6-(trifluoromethyl)-3,4-dihydro-2H-1λ6,2,4-benzothiadiazine-7-sulfonamide
現地名
ベンドロフルメチアジド
英語名
BENDROFLUMETHIAZIDE
分子式
C15H14F3N3O4S2
分子量
421.41

名称と別名

BENDROFLUMETHIAZIDEBendrofluazide73-48-3NaturetinAprinoxBenzhydroflumethiazideBenzylrodiuranCentylPlurylBentrideBristuricBristuron
名称をさらに表示
3-ベンジル-3,4-ジヒドロ-6-トリフルオロメチル-2H-1,2,4-ベンゾチアジアジン-7-スルホンアミド1,1-ジオキシドセンチルベルコジドナツリンベンドロフルメチアジドアプリノックスプルリルナチュレリン3,4-ジヒドロ-3-ベンジル-6-(トリフルオロメチル)-7-(アミノスルホニル)-2H-1,2,4-ベンゾチアジアジン1,1-ジオキシドベンドロフルアジドナツレニンRAC ベンドロフルメチアジドベンドロフルメチアジド (JAN)3-ベンジル-3,4-ジヒドロ-7-スルファミル-6-(トリフルオロメチル)-2H-1,2,4-ベンゾチアジアジン1,1-ジオキシド3-ベンジル-7-スルファモイル-6-(トリフルオロメチル)-1,2,3,4-テトラヒドロ-1,2,4-ベンゾチアジアジン-1,1-ジイウム-1,1-ビス(オラート)ft8bhftft81relanurleablh368nikionorsile
FlumesilNiagarilPlusurilPoliuronSinesalinSodiureticThiazidicoIntolex

物性

構造計算による物性

XLogP
1.2
極性表面積
135 Ų
水素結合供与体数
3
水素結合受容体数
10
回転可能結合数
3
重原子数
27
形式電荷
0
複雑度
740

実験および物理化学的性質

DrugsPharmaceuticals -> Cardiovascular system -> Diuretics
LogP · 3 件

log Kow = 1.19

1.7

1.78

OdorODORLESS OR HAS SLIGHT, CHARACTERISTIC FLORAL ODOR
Color/Form · 2 件

Crystals from dioxane.

WHITE TO CREAM-COLORED, FINELY DIVIDED, CRYSTALLINE POWDER

Solubility · 5 件

FREELY SOL IN ALC & ACETONE

Insoluble in chloroform, benzene, ether.

In water, 108.3 mg/l at 25 °C.

2.14e-01 g/L

>63.2 [ug/mL] (The mean of the results at pH 7.4)

Human Drugs · 4 件

Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Thiazide Diuretics

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Pharmaceuticals

DecompositionWhen heated to decomposition it emits toxic fumes of /hydrogen fluoride/, sulfoxides, and nitroxides.
Melting Point · 3 件

222-223 °C

224.5 to 225.5 °C (also reported as 221 to 223 °C)

221 - 223 °C

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 3 件

This chemical does not meet GHS hazard criteria for 91.5% (54 of 59) of all reports.

Not Classified

Aggregated GHS information provided per 59 reports by companies from 6 notifications to the ECHA C&L Inventory.

危険有害性情報

Regulatory InformationBendroflumethiazide: Does not have an individual approval but may be used under an appropriate group standard
Other Safety InformationIMAP assessments - 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-, 1,1-dioxide: Environment tier I assessment
FDA Requirements · 1 件

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

Hazard Classes and CategoriesNot Classified

安全と保護具

Storage ConditionsBendroflumethiazide tablets should be stored in tight containers at room temperature and protected from excessive heat.
Disposal Methods · 1 件

SRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.

化学と産業

薬理情報

ATC Code · 2 件

C - Cardiovascular system

QC - Cardiovascular system

Protein Binding96%
Pharmacodynamics · 1 件

Bendroflumethiazide, a thiazide diuretic, removes excess water from the body by increasing how often you urinate (pass water) and also widens the blood vessels which helps to reduce blood pressure. It inhibits Na<sup>+</sup>/Cl<sup>-</sup> reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.

Mechanism of Action · 6 件

As a diuretic, bendroflumethiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like bendroflumethiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of bendroflumethiazide is less well understood although it may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.

...BENZOTHIADIAZIDES HAVE DIRECT EFFECT ON RENAL TUBULAR TRANSPORT OF SODIUM & CHLORIDE...INDEPENDENT OF ANY EFFECT ON CARBONIC ANHYDRASE. /THIAZIDE DIURETICS/

NATURE OF CHEM INTERACTION BETWEEN THIAZIDES & SPECIFIC RENAL RECEPTORS RESPONSIBLE FOR CHLORURETIC EFFECT IS NOT KNOWN; NO CRITICAL ENZYMATIC REACTIONS HAVE BEEN IDENTIFIED. /THIAZIDE DIURETICS/

...MAY DECR EXCRETION OF URIC ACID IN MAN, THUS INCR ITS CONCN IN PLASMA. HYPERURICEMIC EFFECT RESULTS PRIMARILY FROM INHIBITION OF TUBULAR SECRETION OF URATE. ... UNLIKE MOST OTHER NATRIURETIC AGENTS...DECR RENAL EXCRETION OF CALCIUM RELATIVE TO THAT OF SODIUM... /ENHANCE/ EXCRETION OF MAGNESIUM... /THIAZIDE DIURETICS/

関連反応

0 件
反応記録を作成

現在のフィルター条件では反応記録がありません。

化合物ノート

読み込み中…

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

データベース識別子

CAS
73-48-3
PubChem CID
2315
DTXSID
DTXSID5022647
ChEMBL
CHEMBL1684
ChEBI
CHEBI:3013
UNII
5Q52X6ICJI
EC Number
200-800-1
Physical Description
Solid
Dissociation Constants8.5
Collision Cross Section · 2 件

188.6 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

189.03 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点
205 · 205-207°C
沸点
602.1 · 602.1±65.0 °C(Predicted)
比重(密度)
1.4711 · 1.4711 (estimate)
貯蔵温度
Refrigerator
溶解性
水にほとんど溶けず、アセトンに溶けやすく、エタノールに溶ける (96%)。
酸解離定数(Pka)
8.53 · pKa 8.53±0.05(H2O t=25 I=0.2) (Uncertain)
外見
Solid
色
3 · MeOH/CHCl3 からの結晶
水溶解度
40 mg/L · 40mg/L(室温)
EPAの化学物質情報
2 H-1,2,4-Benzothiadiazine-7-sulfonamide, · 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 3,4-dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-, 1,1-dioxide (73-48-3)

化学的性質

化学的特性White Solid

毒性情報

Interactions · 5 件

MANY DIABETIC PATIENTS REGULATED BY CHLORPROPAMIDE OR OTHER SULFONYLUREAS EXHIBIT IMPAIRED DIABETIC CONTROL WHEN ANY THIAZIDE DIURETIC IS ADDED TO DRUG REGIMEN. /THIAZIDE DIURETICS/

...CARDIAC GLYCOSIDE & DIURETIC; DIURETIC-INDUCED HYPOKALEMIA POTENTIATES CARDIOTOXICITY OF GLYCOSIDE. /DIURETICS/

THIAZIDES ENHANCE ANTIHYPERTENSIVE ACTION OF GUANETHIDINE, ALLOWING DOSE OF GUANETHIDINE TO BE REDUCED & DECR INCIDENCE OF ADVERSE REACTIONS... /THIAZIDE DIURETICS/

...DIURETICS MAY INCR CONCN OF CLOTTING FACTORS BY LOSS OF PLASMA VOL & INCR CLOTTING FACTOR SYNTH BY REDUCING HEPATIC CONGESTION, THEREBY ANTAGONIZING EFFECT OF ORAL ANTICOAGULANTS. /DIURETICS, THIAZIDE/

For more Interactions (Complete) data for BENDROFLUMETHIAZIDE (21 total), please visit the HSDB record page.

Human Toxicity Excerpts · 3 件

BORDERLINE RENAL &/OR HEPATIC INSUFFICIENCY MAY BE UNPREDICTABLY AGGRAVATED BY THIAZIDES. ... IN CIRRHOSIS OF LIVER, DETERIORATION OF MENTAL FUNCTION, INCL ONSET OF COMA, HAS BEEN ATTRIBUTED TO THIAZIDE THERAPY. ... THIAZIDES MAY INDUCE HYPERGLYCEMIA & AGGRAVATE PREEXISTING DIABETES MELLITUS. /THIAZIDE DIURETICS/

In addition to diuresis and resultant dehydration, overdosage of thiazides may produce lethargy, nausea, weakness, and electrolyte imbalance; lethargy may progress to coma within a few hours with minimal depression of respiratory and cardiovascular function and without evidence of dehydration or serum electryolye change. The mechanism of thiazide-induced CNS depression is unknown. GI irritation and hypermotility may occur, and temporary elevation of the BUN has been reported. Serum electrolyte changes (e.g., hypokalemia, hypochloremia, hyponatremia) may occur, especially in patients with impaired renal function. /Thiazides/

May suppress lactation, but compatible /SRP: with breast feeding/. /Thiazide diuretics, from table/

Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Bendroflumethiazide

vLess-DILI-concern

5

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Antidote and Emergency TreatmentThiazide diuretic overdose should be treated by immediate evacuation of the stomach followed by supportive symptomatic treatment and monitoring of serum electrolyte concentrations and renal function. /Thiazide diuretic/
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Non-Human Toxicity Values · 4 件

LD50 MOUSE ORAL EXCEEDS 8000 MG/KG

LD50 MOUSE INTRAPERITONEAL 8000 MG/KG

LD50 Mouse ip 4800 mg/kg

LD50 Mouse iv 395 mg/kg

EPA Human Health Benchmarks for Pharmaceuticals · 6 件

Bendroflumethiazide

0.1

0.5

Bendroflumethiazide is given in combination with nadolol in a tablet. Each tablet contains 40 mg or 80 mg nadolol combined with 5 mg bendroflumethiazide. Bendroflumethiazide is usually given at a dose of 5 mg daily.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 5 mg/day, Lowest Therapeutic Dose (LTD): 0.1 mg/kg-day, and Screening Dose: 0.00002 mg/kg-day.

15-Apr-16

法規制情報

FDA Requirements · 1 件

Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).

安全データ

wgk
2
rtecs
DK8225000
毒性
LD50 oral in mouse: > 10gm/kg
hs_code
2935904000
有毒物質データの
73-48-3(Hazardous Substances Data)

THIAZIDES INHIBIT REABSORPTION OF SODIUM &...CHLORIDE IN DISTAL SEGMENT. ... AS CLASS...HAVE IMPORTANT ACTION ON EXCRETION OF POTASSIUM THAT RESULTS FROM INCR SECRETION OF CATION BY DISTAL TUBULE. ... GLOMERULAR FILTRATION RATE MAY BE REDUCED BY THIAZIDES, PARTICULARLY WITH IV ADMIN FOR EXPTL PURPOSES. /THIAZIDE DIURETICS/

For more Mechanism of Action (Complete) data for BENDROFLUMETHIAZIDE (11 total), please visit the HSDB record page.

Biological Half-Life · 2 件

8.5 hours

Halflife is 3-3.9 hrs. /From table/

FDA Pharmacological Classification · 6 件

5Q52X6ICJI

BENDROFLUMETHIAZIDE

Physiologic Effects [PE] - Increased Diuresis

Established Pharmacologic Class [EPC] - Thiazide Diuretic

Chemical Structure [CS] - Thiazides

Bendroflumethiazide is a Thiazide Diuretic. The physiologic effect of bendroflumethiazide is by means of Increased Diuresis.

MeSH Pharmacological Classification · 3 件

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Agents that promote the excretion of urine through their effects on kidney function.

Agents that inhibit SODIUM CHLORIDE SYMPORTERS. They act as DIURETICS. Excess use is associated with HYPOKALEMIA.

Absorption, Distribution and Excretion · 6 件

Absorbed relatively rapidly after oral administration

MOST CMPD ARE RAPIDLY EXCRETED WITHIN 3-6 HR. BENDROFLUMETHIAZIDE...LONGER DURATION OF ACTION THAT IS CORRELATED WITH...SLOWER EXCRETION.

THIAZIDES ARE ABSORBED FROM GI TRACT & OWE THEIR USEFULNESS LARGELY TO THEIR EFFECTIVENESS BY ORAL ROUTE. ABSORPTION IS RELATIVELY RAPID. MOST AGENTS SHOW DEMONSTRABLE DIURETIC EFFECT WITHIN HR AFTER ORAL ADMIN. /BENZOTHIADIAZIDES/

IN GENERAL, THIAZIDES WITH RELATIVELY LONG DURATIONS OF ACTION SHOW PROPORTIONATELY HIGH DEGREE OF BINDING TO PLASMA PROTEINS & ARE REABSORBED... BY RENAL TUBULES. ... DRUG PASSES READILY THROUGH PLACENTAL BARRIER TO FETUS. ALL THIAZIDES PROBABLY UNDERGO ACTIVE SECRETION IN PROXIMAL TUBULE. /THIAZIDE DIURETICS/

BENDROFLUMETHIAZIDE WAS ADMIN ORALLY TO 9 HEALTHY VOLUNTEERS. PEAK PLASMA LEVELS REACHED @ 1 + OR - 0.4 HR. CONCN DECLINED WITH MEAN T/2 OF 3 HR. APPARENT VOL OF DISTRIBUTION AVG 1.48 L/KG. MAJOR PART ELIMINATED VIA NONRENAL MECHANISMS. URINARY RECOVERY AVG 30%.

Bendroflumethiazide appears to be well absorbed from the GI tract. The drug is excreted unchanged in urine, and excretion is essentially complete within 24 hours.

Cellular LocationsCytoplasm
Metabolite PathwaysBendroflumethiazide Action Pathway

用途と製造

Uses · 2 件

MEDICATION

THERAP CAT: Diuretic, antihypertensive.

Methods of ManufacturingPrepn: C.T. Holdrege et al., J Am Chem Soc 81, 4807 (1959); F. Lund, W.O. Godtfredsen, Brit pat 863,474; eidem, U.S. pat 3,392,168 (1961, 1968 both to Lovens Kemiske Fabrik)..
Formulations/PreparationsDOSAGE FORMS- TABLETS NF: 2.5, 5, & 10 MG.
Use ClassificationPharmaceuticals
応用分野 · 2 件

説明Bendroflumethiazide (Item No. 21311) is an analytical reference standard categorized as a diuretic. Diuretics, including bendroflumethiazide, have been abused as performance-enhancing drugs and masking agents in sports doping. This product is intended for research and forensic applications.

使用Bendroflumethiazide may be used for the same indications as the aforementioned drugs; however, it is primarily used as an adjuvant agent for relieving edema associated with cardiac insufficiency, liver cirrhosis, and edema caused by taking corticosteroids.

上流・下流製品情報

上流原料

3-ニトロベンゾトリフルオリドベンゾトリフルオリドAminosulfonateベンゾトリクロリドフェニルアセトアルデヒド鉄粉3-アミノベンゾトリフルオリドアンモニアクロロスルホン酸

サプライヤー73 社

国药集团化学试剂有限公司86-21-63210123 · [email protected]
北京华美互利生物化工010-56205725 · [email protected]
阿诺西(上海)生物技术有限公司400-1107768 15058188853 · [email protected]
上海阿拉丁生化科技股份有限公司400-6206333 13167063860 · [email protected]
南通飞宇生物科技有限公司0513-68819626 15152877458 · [email protected]
艾吉析科技(上海)有限公司17717235263 · [email protected]
HubeiwidelychemicaltechnologyCo.,Ltd18627774460 · [email protected]
普善实业(陕西)有限公司029-81310890 18165209495 · [email protected]
Syntechem Co.,Ltd[email protected]
广东元丰化学试剂有限公司0751-2829979 13318593351 · [email protected]
成都梓永智研生物科技有限公司17780686372 · [email protected]
西安泽邦生物科技有限公司[email protected]
天津万象恒远科技有限公司15722085254 · [email protected]
广州济成进出口贸易有限公司13682223272 · [email protected]
Moxin Chemicals+86-17320513646 +86-17320513646 · [email protected]
ZHEJIANG JIUZHOU CHEM CO., LTD+86-0576225566889 +86-13454675544 · [email protected];[email protected];[email protected]
上海明褀化学有限公司86-21-60936353
深圳振强药物研发有限公司0755-66853366 13670046396 · [email protected]
南京生利德生物科技有限公司025-57798810 18652991625 · [email protected]
武汉鹏胤药业有限公司13163333255 · [email protected]
PT CHEM GROUP LIMITED+86-85511178; +86-85511178 · [email protected]
北京奥秘佳得医药科技有限公司+86-13522808617 · [email protected]
四川省维克奇生物科技有限公司028-81700200 18116577057 · [email protected]
天津普西唐生物医药科技有限公司010-60605840 · [email protected]
江苏艾康生物医药研发有限公司025-66028182 17714375163 · [email protected]
Xiamen Eagle Chemical Limited Corporation+86-18900207489 · [email protected]
Chongqing jooe co., ltd+86-15223382610 · [email protected]
LUYUNJIA CHEMISTRY XIAMEN LIMITED+86-592-5360779 +86-13055435203
凯试(上海)科技有限公司021-50135380 · [email protected]
HANGZHOU LEAP CHEM CO., LTD.+86-571-87711850 +86-15355479329 · [email protected]
艾吉析科技(上海)有限公司17717235263 17717235263 · [email protected]
Anhui Ruihan Technology Co., Ltd+undefined17756083858 · [email protected]
上海珞珐生化科技有限公司021-51111890 15317326293 · [email protected]
成都大道三灵生物科技有限公司18108108965 18108108965 · [email protected]
上海前衍生物科技有限公司02781293128 · [email protected]
成都华纯科技有限公司400-1166-196 15982826727 · [email protected]
深圳市森迪生物科技有限公司18126413629 0755-23311925 2355327053 · [email protected]
上海乾平生物医药科技有限公司(宁波仓库发货)021-61537865 13585780846 · [email protected]
深圳市森迪生物科技有限公司18124570582 TEL:0755-23574479 2355327139 · [email protected]
广州卡芬生物科技有限公司18029243487 2355327168 · [email protected]
武汉曙欧科技有限公司17792809151;18872220797 · [email protected]
深圳市祥根生物医药有限公司0755-28967200 13631290199 · [email protected]
Shanghai Acmec Biochemical Technology Co., Ltd.+86-18621343501 · [email protected]
珠海嘉亿生物科技有限公司18578209868 2355327026 · [email protected]
上海臻励生物科技有限公司021-16621358918; 18516310516;16621358918;13045646768 · [email protected]
深圳市森迪生物科技有限公司0755-23311925 18102838259 · [email protected]
河南天孚化工有限公司+86-0371-55170693 +86-19937530512 · [email protected]
佛山道麒生物科技有限公司18062666947 · [email protected]
广州千行进出口有限公司020-37651955 13682223272 · [email protected]
上海宏叶生物科技有限公司400-9205774 400-920-5774 · [email protected]

補足説明

定義ChEBI: A sulfonamide consisting of 7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by a trifluoromethyl group and that at position 3 is substituted by a benzyl group.